Brief: ChemoCentryx’s Oral PD-L1 Inhibitor Featured In Poster Presentation At 2021 American Association For Cancer Research Annual Meeting
09/04/2021 13:38
April 9 (Reuters) - ChemoCentryx Inc CCXI.O :
* CHEMOCENTRYX’S ORAL PD-L1 INHIBITOR, CCX559, FEATURED IN
POSTER
PRESENTATION AT THE 2021 AMERICAN ASSOCIATION FOR CANCER
RESEARCH (AACR) ANNUAL MEETING
* CHEMOCENTRYX INC - PLANS TO ADVANCE CCX559 INTO CLINICAL
DEVELOPMENT IN FIRST HALF OF 2021
* CHEMOCENTRYX INC - CCX559 ENHANCED PRIMARY HUMAN T CELL
ACTIVITY
IN VITRO AND DEMONSTRATED ANTI-TUMOR EFFICACY IN TWO MURINE
TUMOR MODELS
Source text for Eikon: ID:nGNX54y2hH
Further company coverage: CCXI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Churchill Capital XI
See all newsBrief: AGCO To Pilot Digit Humanoid Robot At Hesston, Kansas Facility In 2027
Brief: Agility Robotics Announces Audit Committee Chair For Planned Public-Company Board
Brief: Agility Robotics And Churchill Capital Corp Xi S-4 Registration Statement Declared Effective By SEC In Connection With Proposed Business Combination
Brief: Agility And Fort Robotics Announce Strategic Partnership To Advance Humanoid Robot Safety
Deals of the day-Mergers and acquisitions